Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 9/20 | 0.42 |
| ▸ | GRM5 | P41594 | 8/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 4/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23581043 | 1.00 | NAMPT (0.44) | NAMPTGRM1GRM5CNR1KIT | |
| SCHEMBL23580352 | 0.84 | GRM1 (0.46) | NAMPTGRM1GRM5CNR1KIT | |
| SCHEMBL30340768 | 0.84 | GRM1 (0.46) | NAMPTGRM1GRM5CNR1KIT | |
| SCHEMBL30178579 | 0.75 | CNR1 (0.51) | NAMPTGRM1GRM5CNR1CDK7 | |
| SCHEMBL15188268 | 0.73 | ENPP2 (0.54) | NAMPTGRM1GRM5CNR1ENPP2 | |
| SCHEMBL15534537 | 0.73 | NAMPT (0.52) | NAMPTGRM1GRM5CNR1ENPP2 | |
| SCHEMBL31548749 | 0.72 | BTK (0.49) | NAMPTGRM1GRM5CNR1CDK7 | |
| SCHEMBL18081229 | 0.71 | PDK4 (0.51) | NAMPTGRM1GRM5CNR1PDK4 | |
| SCHEMBL31083549 | 0.71 | GRM1 (0.48) | NAMPTGRM1GRM5CNR1PDK4 | |
| SCHEMBL25311684 | 0.71 | GRM1 (0.48) | NAMPTGRM1GRM5CNR1PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569485-B2 | SMARCA inhibitors and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | SMARCC1, SMARCE1, SMARCA1 | NAMPT 1726/4885GRM1 4369/4885GRM5 4470/4885 |
| US-12569485-B2 | SMARCA inhibitors and uses thereof | SMARCC1, SMARCC2, SMARCA2 | NAMPT 3501/4885GRM1 3471/4885GRM5 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.